Zhongjing Medicine Completes Multi-Million RMB Angel Funding Round to Advance Non-Invasive Urinary Tract Cancer Diagnostics

Recently, Qingdao Zhongjing Puhui Medical Technology Co., Ltd. (hereinafter referred to as “Zhongjing Medical”) announced that it had completed an angel financing round worth several million yuan earlier, jointly invested by Bolian Capital and Chongyi Capital. This financing will help the company complete the multi-center clinical trials of its urothelial carcinoma auxiliary diagnostic kit and apply for Class III medical device certification.

Zhongjing Medicine is jointly established by top clinical experts and in vitro diagnostic technology teams in China.Urologic Oncology Precision Diagnosis and Treatment Enterprise.Drawing on decades of clinical experience, the team has achieved creative breakthroughs in key technologies,Early screening, targeted diagnosis, and treatment of urothelial carcinoma (including bladder cancer, ureteral cancer, renal pelvic cancer, etc.) can be achieved through in vitro urine testing.Significantly improving the early diagnosis rate, cure rate, and quality of life for urologic tumors represents a leading technological breakthrough.

Malignant tumors of the urinary system are common conditions in urology. Among them, urothelial carcinoma (UC) is the most prevalent malignant tumor of the urinary system, primarily including bladder cancer, ureteral cancer, and renal pelvic cancer. In China, there are over 80,000 new cases of these diseases annually.

Urothelial carcinoma is highly insidious in onset, often presenting with painless hematuria as an initial symptom, which makes effective differential diagnosis from conditions such as calculi and inflammation difficult in the early stages. Currently, the clinical gold standard for diagnosis involves endoscopic sampling procedures, such as cystoscopy and ureteroscopy. These invasive diagnostic techniques require hospitalization and cannot be performed directly in outpatient settings. As invasive tests, they carry risks of hematuria, pain, and infection, while also being limited by low throughput, long waiting times, and high overall costs. Furthermore, they have a lower detection rate for small lesions, leading to poor patient compliance and often delaying optimal treatment timing.

Traditional non-invasive diagnostic techniques, represented by urinary exfoliated cytology and fluorescence in situ hybridization (FISH) testing, suffer from high false-negative rates (approximately 50% for urinary exfoliated cytology and nearly 30% for FISH), stringent sampling requirements, high demands on operator proficiency, and substantial costs (RMB 2,400–3,000 per FISH test). Consequently, these methods fail to meet clinicians’ needs for early screening and diagnosis.

In response to the aforementioned clinical needs, the scientific team at Zhongjing Medicine has collaborated closely with senior experts from the Urology Institute of Peking University. Through in-depth research on the epigenomics of a large cohort of patients with urothelial carcinoma, they have identified multiple epigenetic biomarker alterations closely associated with the onset and progression of urothelial carcinoma, with varying weights assigned to the impact of different biomarkers on the tumor.

Based on the above findings, Zhongjing Medicine has successfully developedDetection Technologies for Molecular Biomarkers in Urothelial Carcinoma,"Using genetic material from patient urine as a testing sample, non-invasive precision-assisted tumor diagnosis has been achieved."In preliminary single-center studies, this technology served as an adjunctive diagnostic tool for patients with hematuria.The average sensitivity can reach 89%, the average specificity can reach 74%, and the average AUC can reach 87.6%.In comparative studies using patient samples, the aforementioned assay demonstrated superior performance to urine exfoliated cytology and fluorescence in situ hybridization (FISH) testing.

Meanwhile, Zhongjing Medical alsoCreatively developed an adjunctive diagnostic protocol for urothelial carcinoma based on a “microscopy-plus-molecular” dual-methodology approach,Can be achievedAverage sensitivity 92%, average specificity 93.7%, average AUC 93.7%, average PPV 98%detection performance, comprehensively improving the accuracy of non-invasive diagnostic testing for urothelial carcinoma.

Zhongjing Medicine is headquartered in the Shibei District of Qingdao, with a research and development (R&D) center established in Beijing. The founding team possesses extensive experience in R&D, operations, and marketing within the fields of medical laboratory testing and in vitro diagnostics (IVD). Team members include senior executives from renowned domestic and international pharmaceutical and biotechnology companies such as Bayer Pharma, Zhongke Gene, and Meian Gene. The company has established in-depth collaborations with medical institutions including Peking University First Hospital, Beijing Ciming Health Checkup, and Haier International Cell Bank, accumulating substantial expertise in tumor molecular diagnostics. Zhongjing Medicine boasts an experienced team of experts and an advanced R&D platform. The company provides a closed-loop, non-invasive clinical solution for urothelial carcinoma, encompassing auxiliary diagnosis, molecular subtyping, dynamic monitoring, high-risk screening, and companion diagnostics. Through breakthroughs in advanced, non-invasive, and accessible precision diagnosis and treatment technologies, Zhongjing Medicine enables more patients to achieve early detection, early diagnosis, and early treatment.

Bolian Zichuang is a platform co-founded by scientists and PhD experts across multiple disciplines, focusing on incubating projects in core technology fields. It deeply invests in high-tech enterprises in pharmaceuticals and healthcare, advanced manufacturing, and artificial intelligence, helping to unleash the impact of technological industries and achieve value investment for startups.

Chongyi Capital, established in the Tianjin Free Trade Zone, is an investment platform co-founded by executives of listed companies and senior technology experts. Its founders possess extensive entrepreneurial experience in frontier deep-tech industries, as well as expertise in financing, investment, and mergers and acquisitions. Dedicated to the long-term incubation of strategic hard-tech sectors such as biopharmaceuticals, intelligent manufacturing, and integrated circuits, Chongyi Capital supports projects that aim to break through key core technologies and address critical bottlenecks. By providing multidimensional resources—including talent, capital, industry connections, and market access—it empowers enterprises and accompanies their long-term growth.